Innovating Works

BosomShield

Financiado
A comprehensive CAD system based on radiologic- and pathologic-image biomarkers for diagnosis and prognosis of breast cancer relapse Breast cancer (BC) incidence in women produces more than 600,000 deaths each year. The primary cause of death in BC patients is metastasis, whereby cancer cells spread from their primary site of origin and grow in adjacent or dist... Breast cancer (BC) incidence in women produces more than 600,000 deaths each year. The primary cause of death in BC patients is metastasis, whereby cancer cells spread from their primary site of origin and grow in adjacent or distant sites. Distant metastasis produced due to the relapse of the illness is incurable, underscoring the inadequacy of our understanding of its mechanisms. The first step for fighting against disease progression is screening programs for BC focused on image analysis of mammography, MRI and tomosynthesis. Once the tumour has been diagnosed and given the high variability of clinical progressions, another problem arises: classifying the cancer type and determining the proper treatment for specific cancer. Moreover, in BC, the immune response from the tumour microenvironment has played an essential role in tumour evolution. To evaluate the tumour and its microenvironment, one technique garnered a lot of attention in the last years: Whole Slide Imaging (WSI). This technique replaces the use of the microscope for classical diagnosis. Still, it has also been used for developing biomarkers that allow the analysis of tumours and classification of cancer subtypes and the study of the immune tumour microenvironment. The use of WSI has applications for predicting the probability of relapse for distant metastasis. Now, for the first time, BosomShield proposes to join the two disciplines (pathological and radiological imaging) in a software that will analyze these images to classify the cancer subtypes and predict (together with the complete clinical history of the patient) the probability of relapse for distant metastasis. Besides, BosomShield will provide high-level training in BC research to young researchers by offering the necessary transferable skills for thriving careers underpinned using diverse disciplines, digital radiology and pathology, biomedical, AI, privacy and software development. ver más
31/08/2026
UNIVERSIDAD ROVIRA I VIRG...
Presupuesto desconocido
Duración del proyecto: 49 meses Fecha Inicio: 2022-07-06
Fecha Fin: 2026-08-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-07-06
HORIZON EUROPE No se conoce la línea exacta de financiación, pero conocemos el organismo encargado de la revisión del proyecto.
Líder del proyecto
UNIVERSIDAD ROVIRA I VIRGILI No se ha especificado una descripción o un objeto social para esta compañía.